Compare MRT & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MRT | PYXS |
|---|---|---|
| Founded | 2018 | 2018 |
| Country | Turkey | United States |
| Employees | N/A | N/A |
| Industry | Rental/Leasing Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 176.2M | 141.3M |
| IPO Year | 2021 | 2021 |
| Metric | MRT | PYXS |
|---|---|---|
| Price | $1.76 | $3.06 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $3.58 | ★ $7.00 |
| AVG Volume (30 Days) | 34.5K | ★ 1.6M |
| Earning Date | 08-08-2018 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.03 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,858,000.00 |
| Revenue This Year | $72.36 | N/A |
| Revenue Next Year | $95.75 | $7,043.98 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.12 | $1.03 |
| 52 Week High | $2.75 | $5.55 |
| Indicator | MRT | PYXS |
|---|---|---|
| Relative Strength Index (RSI) | 52.30 | 52.82 |
| Support Level | $1.63 | $1.37 |
| Resistance Level | $1.87 | $3.40 |
| Average True Range (ATR) | 0.11 | 0.45 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 57.69 | 55.71 |
Marti Technologies Inc is Turkiye's urban mobility platform, helping to solve the country's transportation needs through tech-enabled services powered by a single mobility super app. The Group aims to offer tech-enabled urban transportation services to consumers across Turkiye through three service offerings: ride-hailing, delivery, and two-wheeled electric vehicle services. The Group's ride-hailing service matches consumers with car, motorcycle, and taxi drivers. The Group's delivery service provides same-hour package delivery by leveraging the Group's existing network of car and motorcycle drivers and consumer base.
Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.